Skip to main content
. 2020 Aug 10;130(9):4921–4934. doi: 10.1172/JCI138392

Figure 5. Administration of TCMCB07 s.c. reverses cachexia associated with CKD in rats.

Figure 5

(A) Schematic of experimental design. Two-stage 5/6 nephrectomy or sham operation was performed in Sprague-Dawley rats. Stage I of 5/6 nephrectomy was Neph-I and stage II was Neph-II. All animals experienced Neph-I and Neph-II or sham operation on day 0 and day 7 and received s.c. injection twice (2×) daily with saline or TCMCB07 (3 mg/kg/d) between day 14 and day 28 after nephrectomy. Neph/saline group (n = 11), neph/TCMCB07 group (n = 11), and sham/saline group (n = 6). (B) Body weight change during entire experimental period (days 0–28, after nephrectomy). (C) Body weight gain (%, net gain normalized to baseline) after nephrectomy and after treatment. (D) Daily food intake in neph/saline, neph/TCMCB07, and sham/saline groups after treatment. (E) Cumulative food intake after treatment. (F) Fat mass and (G) lean mass were determined by MRI before (day 14) and after (day 28) treatment, and the gain (%) was calculated (net gain normalized to baseline). All data in B and D are expressed as mean ± SEM for each group, and all data in C and E–G are expressed with each dot representing 1 sample. *P < 0.05; ****P < 0.0001; #P < 0.05; ##P < 0.01; ###P < 0.001, 2-way ANOVA (B–E); unpaired Student’s t test (F and G). Blue asterisks in B and D indicate neph/saline group versus sham/saline group, and red pound signs in B and D indicate neph/TCMCB07 group versus neph/saline group.